Genprex has maintained Nasdaq listing compliance through a Nasdaq Hearings Panel exception following a reverse stock split and continues to monitor compliance requirements. The company reported net losses and liquidity sufficient to fund operations into mid-2027. It continues research collaborations and intellectual property development in gene therapy for diabetes and oncology.

• On July 29, 2026, the Nasdaq Hearings Panel granted Genprex an exception to demonstrate compliance with the minimum bid price requirement, with compliance maintained through December 7, 2026, following a hearing on July 21, 2026 [S2].
• Genprex implemented a one-for-twenty-two reverse stock split effective July 16, 2026, as part of efforts to maintain Nasdaq listing compliance [S2].
• The company reported net losses of approximately $4.45 million for the quarter ended June 30, 2026, and held cash and cash equivalents of about $15.15 million at that date, supporting operations into the second quarter of 2027 [S2].
• Genprex formed a wholly-owned subsidiary, Convergen Biotech, Inc., in February 2025 to potentially separate its diabetes clinical development program from oncology assets [S1].
• The company holds exclusive worldwide licenses for gene therapy technologies from the University of Pittsburgh, including patents related to gene therapy for Type 1 and Type 2 diabetes [S1].

The company’s exclusive licenses and intellectual property portfolio in gene therapy for diabetes and oncology provide a foundation for potential future therapeutic products. Preclinical data presented by collaborators indicate promising therapeutic effects in non-human primate models, supporting the scientific rationale for its gene therapy candidates. The formation of a dedicated subsidiary for the diabetes program could enable focused development and commercialization efforts. Genprex’s liquidity position as of mid-2026 supports ongoing clinical activities into 2027, allowing continued advancement of its pipeline.

Genprex has no current revenue and has sustained substantial operating losses since inception, with net losses continuing in recent quarters. The company depends on raising additional capital to fund operations and clinical development, with no assurance of successful financing. It faces risks related to maintaining Nasdaq listing compliance, including minimum bid price and market value requirements, with potential delisting posing material adverse effects on its business and capital access. The clinical and regulatory risks inherent in gene therapy development, combined with competitive pressures and the early stage of its programs, add uncertainty to its prospects.

Genprex’s moat is primarily based on its exclusive licensing agreements with the University of Pittsburgh for proprietary gene therapy technologies, including patents and related know-how for gene therapies targeting diabetes and oncology. The company’s intellectual property portfolio, consisting of multiple granted patents and pending applications worldwide, provides legal protection for its therapeutic approaches. Additionally, its collaborations with academic institutions and contract development organizations support its research and development efforts. However, as a clinical-stage company without commercial products or revenue, its competitive position depends heavily on successful clinical development and regulatory approvals, which remain uncertain.

• Capital and Liquidity Risk: Genprex has sustained losses and no current revenue, requiring additional capital to fund operations and clinical trials. Failure to raise sufficient funds could materially affect its financial condition and operations.
• Nasdaq Listing Compliance Risk: The company must maintain minimum bid price and stockholders’ equity requirements to remain listed on Nasdaq. Recent reverse stock splits and a granted exception highlight ongoing risk of delisting, which could adversely impact stock price and capital access.
• Clinical and Regulatory Risk: As a clinical-stage company, Genprex faces risks inherent in clinical development and regulatory approval processes for its gene therapy candidates, which may delay or prevent commercialization.
• Operational Risk: The company’s ability to execute its business plan depends on successful collaborations, intellectual property protection, and management of research and development activities.

• Genprex, Inc. is a clinical-stage gene therapy company focused on developing gene therapies for oncology and diabetes indications.
• The company holds exclusive worldwide licenses for certain gene therapy technologies from the University of Pittsburgh, including patents related to gene therapy for Type 1 and Type 2 diabetes using Pdx1 and MafA transcription factors controlled by insulin, glucagon, and MafB promoters.
• Genprex has a wholly-owned subsidiary, Convergen Biotech, Inc., formed in February 2025 to potentially separate the diabetes clinical development program from oncology programs.
• The company has sustained substantial losses since inception and has no current source of revenue, with reported net losses of approximately $4.45 million for the quarter ended June 30, 2026.
• As of June 30, 2026, Genprex had cash and cash equivalents of approximately $15.15 million and a current ratio of 6.77, indicating liquidity sufficient to fund operations into the second quarter of 2027 based on current plans.
• Genprex completed reverse stock splits in 2024 (1-for-40) and 2025 (1-for-50), and a 1-for-22 reverse stock split effective July 16, 2026, to maintain Nasdaq listing compliance.
• The company’s common stock is listed on Nasdaq but has faced challenges maintaining the minimum bid price requirement of $1.00 per share, resulting in a Nasdaq Hearings Panel granting an exception to demonstrate compliance through December 7, 2026.
• Genprex must maintain compliance with Nasdaq listing requirements, including minimum bid price and stockholders’ equity thresholds, or risk delisting, which could materially affect its business and capital access.
• The company’s intellectual property portfolio includes 15 granted patents and 28 pending patent applications worldwide, covering therapeutic, diagnostic, technical, and processing claims.
• Research and development expenditures include payments to collaborative research partners, manufacturing partners, consultants, and clinical strategy partners, with materials costs capitalized when they have alternative future use and expensed otherwise.
• The company’s consolidated financial statements are prepared under US GAAP and reflect normal recurring accruals; no impairments of long-lived assets were recorded for 2024 or 2025.
• Genprex’s clinical collaborators have presented preclinical data on gene therapy candidates in non-human primate models of Type 1 diabetes, showing therapeutic potential.
• The company recognizes risks related to its ability to raise additional capital, maintain Nasdaq listing compliance, and continue as a going concern due to recurring losses and lack of revenue.